Compare MKTW & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKTW | BOLD |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 36.5M |
| IPO Year | 2020 | 2024 |
| Metric | MKTW | BOLD |
|---|---|---|
| Price | $17.58 | $1.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $4.00 |
| AVG Volume (30 Days) | 24.9K | ★ 407.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | ★ 1183.33 | 32.47 |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.65 | $0.96 |
| 52 Week High | $21.74 | $1.78 |
| Indicator | MKTW | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 57.09 |
| Support Level | $16.06 | $1.08 |
| Resistance Level | $20.62 | $1.55 |
| Average True Range (ATR) | 0.87 | 0.09 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 77.84 | 58.04 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.